Sciogen LLC
Los Altos, CA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Sole Proprietorship
- SAM.gov registration date
- Physical address
- 718 Terrace Ct, Los Altos, CA 94024, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
About the company
Sciogen LLC is a for-profit limited liability company that provides biopharmaceutical research and development services to the federal government through federal grant awards. It specializes in the development of vaccine candidates, particularly for respiratory viruses like respiratory syncytial virus (RSV).
Sciogen LLC has received prime federal grant awards from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of a novel G protein-based RSV vaccine candidate. The awarded projects aim to optimize and further develop this promising vaccine through process and analytical method development, evaluation in animal models, and conducting GLP toxicology studies. These grants, totaling over $4 million in funding, will facilitate the advancement of Sciogen's RSV vaccine candidate towards clinical studies. Additionally, Sciogen has received a sub-grant award from Purilogics LLC, a prime grantee, to assist in the evaluation of membrane column performance for the purification of a recombinant vaccine antigen produced by Sciogen. This collaboration involves Sciogen providing purified recombinant vaccine samples and conducting purification tests using Purilogics' affinity membrane columns to optimize binding capacity, recovery, and purity.
Quick answers
Is Sciogen LLC registered in SAM.gov?
Yes. Sciogen LLC's SAM.gov registration is active through July 30, 2027.
What is Sciogen LLC's CAGE code?
Sciogen LLC's CAGE code is 7E8Y5, and its Unique Entity ID (UEI) is RGEHAJ63EJK5.
What is Sciogen LLC's most recent federal award?
Sciogen LLC's most recent federal grant award is Novel respiratory syncytial virus therapeutics targeting G-receptor binding - the overall objective of this phase I… (R43AI191860), from National Institute of Allergy and Infectious Diseases (NIH), on September 1, 2026.
On GovTribe
See Sciogen LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors